Across TCGA pan-cancer cohorts, PLXNB2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLXNB2 data layer compared with 25 for mass-spec protein and 15 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PLXNB2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLXNB2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where PLXNB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.771	0.875	.011	11	view →
CCRCC	OS	Quartile	All	1.000	0.430	.021	10	view →
LSCC	OS	Median	All	0.701	0.876	.029	4	view →
LUAD	DFS	Quartile	All	0.866	1.000	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PLXNB2 tumor-vs-normal RNA expression · all PLXNB2 data types